Immune Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development and commercialization of targeted therapeutics in the fields of immuno-inflammation, dermatology and immuno-oncology. Co.'s primary product candidate, bertilimumab, is a human antibody, which targets eotaxin-1, a key regulator of immuno-inflammation. NanoCyclo is a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Co.'s pain programs also include AmiKet™ / AmiKet Nano, a prescription topical analgesic cream, and LidoPAIN, an adhesive-backed, lidocaine-based patch for the treatment of lower back pain. We show 7 historical shares outstanding datapoints in our coverage of IMNP's shares outstanding history.
Understanding the changing numbers of IMNP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like IMNP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching IMNP by allowing them to research IMNP shares outstanding history
as well as any other stock in our coverage universe. |
Free IMNP Email Alerts:
Video: Shares Outstanding Importance
